- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Aetna chairman Ron Williams to retire, Mark T. Bertolini to become CEO
Aetna Chairman and CEO Ronald A. Williams will retire from Aetna in April 2011. On Nov. 29, 2010, Mark T. Bertolini will be appointed chief executive officer and elected to the company?s Board of Directors.
Aetna Chairman and CEO Ronald A. Williams, 60, will retire from Aetna in April 2011. On Nov. 29, 2010, Williams will become executive chairman and Mark T. Bertolini, 54, currently Aetna’s president and head of Business Operations, will be appointed chief executive officer and elected to the company’s Board of Directors.
The Board intends to elect Bertolini to the additional role of chairman of the Board upon the retirement of Williams, according to Aetna.
Bertolini joined Aetna in February 2003 and held a series of roles with increasing responsibilities before being named president in July 2007. Prior to joining Aetna, Bertolini held positions with Cigna and NYLCare and had been chief executive officer of SelectCare.
Aetna said that in his full-time role as executive chairman, Williams will focus on board duties as well as Aetna’s Chairman’s Initiatives, public policy and federal regulatory strategy. Following his retirement from Aetna, Williams has agreed to provide consulting services to Aetna and the Aetna Foundation through February 2012.
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More
Omega-3s For Dry Eye Disease? Not the Answer According to This Study
May 17th 2024Some research has suggested that omega-3 fatty acid supplements could help treat dry eye disease. But Korean investigators reported results from a randomized clinical trial this week in JAMA Ophthalmology tthat showed no benefit.
Read More
